Author(s):
Raghuveer V. Patil, Azam Z. Shaikh, Akash S. Jain, Divakar R. Patil, Sameer R. Shaikh, S.P. Pawar
Email(s):
azamph46@gmail.com
DOI:
10.52711/2231-5713.2024.00064 
Address:
Raghuveer V. Patil*, Azam Z. Shaikh, Akash S. Jain, Divakar R. Patil, Sameer R. Shaikh, S.P. Pawar
Department of Pharmaceutics P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra-425409, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 4,
Year - 2024
ABSTRACT:
Healthcare spending on medications is rising due to advancements in medical care and increased diagnostic capabilities for conditions like high blood pressure and diabetes. Medicines are categorized into branded and generic drugs. A significant portion of healthcare spending is dedicated to medicines, with future costs expected to rise due to advancements in healthcare, improved diagnostics, and demographic changes. Medicines are primarily classified into branded and generic drugs. Branded drugs are original products developed by pharmaceutical companies and protected by patents, which grant exclusive manufacturing and marketing rights for a set period. This results in high production and marketing costs, leading to elevated prices. Once the patent expires, Generic drugs which are identical in form, strength, administration, quality, and therapeutic effect become available. Generics are produced at lower costs due to reduced manufacturing, marketing, and retailer expenses, making them a cost-effective alternative. Although generics might vary in appearance or taste due to different fillers, they are just as safe and effective as branded drugs. The adoption of generics is influenced by public policies aimed at reducing healthcare costs and can help lower overall expenditures while maintaining high care standards. By making generics more accessible, healthcare systems can potentially reduce overall costs while maintaining high standards of patient care.
Cite this article:
Raghuveer V. Patil, Azam Z. Shaikh, Akash S. Jain, Divakar R. Patil, Sameer R. Shaikh, S.P. Pawar. A Short Review on Description of Generic and Branded Drug. Asian Journal of Pharmacy and Technology. 2024; 14(4):407-1. doi: 10.52711/2231-5713.2024.00064
Cite(Electronic):
Raghuveer V. Patil, Azam Z. Shaikh, Akash S. Jain, Divakar R. Patil, Sameer R. Shaikh, S.P. Pawar. A Short Review on Description of Generic and Branded Drug. Asian Journal of Pharmacy and Technology. 2024; 14(4):407-1. doi: 10.52711/2231-5713.2024.00064 Available on: https://ajptonline.com/AbstractView.aspx?PID=2024-14-4-17
REFERENCES:
1. Garrison GM, Oberhelman S. Screening for Hypertension Annually Compared with Current Practice. Annals of Family Medicine. 2013; 11(2): 116-121.
2. Generic medicines and Branded medicines. Available at http://www.myvmc.com/treatments/generic medicines and branded medicines. Accessed 15 October 2014.
3. Generic Drugs, Available at http://www.who.int/trade/glossary/ story034/en/WHO. Accessed 15 October 2014.
4. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croat Med J. 2002; 43(4): 462-9.
5. Guidance on INN, WHO Available at http://www.who. Int/medicines/services/inn/inn guidance/en/index.html. Accessed 15 October 2014.
6. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009; 43:1583–97.
7. Singal G, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol. 2011; 43:131–6.
8. www.wikipedia.org/ Branded and Generic Drug
9. Campbell, Jonathan D., Belozeroff, Vasily, Whittington, Melane D., Rubin, Robert J., Raggi, Paolo, and Briggs, Andrew H. Prices for Common Cardiovascular Drugs in the US are not Consistently Aligned with Value. Health Affairs. 2018; 37(8): 1298–1305.
10. U.S. Food and Drug Administration (FDA). The Drug Development Process. 2022. Retrieved from [FDA Website] (https://www.fda.gov/patients/drug-development-process/step-3-clinical-research)
11. European Medicines Agency (EMA). (2021). Clinical trials in human medicines. Retrieved from [EMA Website] (https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines)
12. World Health Organization (WHO). (2021). Clinical trials. Retrieved from [WHO Website] (https://www.who.int/health-topics/clinical-trials#tab=tab_1)
13. National Institutes of Health (NIH). (2023). NIH Clinical Research Trials and You. Retrieved from [NIH Website] (https://www.nih.gov/health-information/nih-clinical-research-trials-you)
14. National Center for Biotechnology Information (NCBI). (2020). Clinical Trials Phases. Retrieved from [NCBI Website] (https://www.ncbi.nlm.nih.gov/books/NBK526019/)